U.S. Food and ‌Drug Administration staff reviewers said on Tuesday data demonstrating an immune response to Moderna's flu ...
Pharmaceutical Technology on MSN
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway
The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age ...
The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...
Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA ...
The company's pending vaccine approvals could help the stock continue its rise.
CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 ...
VWAP resistance, R&D wins, Q1 revenue surge, and mRNA-1010 risks missed flu contracts—the rating shifts to Sell. Click for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results